Didier Letourneur Biomedical Engineer

Course and current status


1980 - 1985    Engineer In Material Science, University Paris 13 (UP13-USPN)

1984 - 1985    Master (DEA) in Bio-engineering; Specialty : Biomaterials

1988               Ph.D. in Chemistry, University Paris 13

1994               Specialization Degree "Experimentation on Animals", University Paris 6

1997               Habilitation (Ph.D. Direction), UP13


From 2002     Research Director DR2 CNRS - DR1 from 2011 - DRCE from 2020

From 2005     Head of Bio-Engineering team 3 INSERM U698 & Head of Research            

                     Technological team (ERTi). From 2002 to 2004 Head ERIT-M 0204 Inserm

From 2009     President of Biomat (French association for Biomaterials) until 2019

                     Honorary President from 2019                    

From 2014     Director Inserm U1148-University Paris Cité-Univ Sorbonne Nord                   

                     (250 persons) until Dec 2024

2016             President LS7 ATIP/AVENIR - Member LS7 panel in 2013 and 2014

2016-2021     President CSS7 Inserm (Health technologies & Public Health)  

From 2022     President of the Scientific Council of INSERM

Scientific summary

Cardiovascular Bio-engineering Laboratory – INSERM U 1148

Headed by Didier Letourneur (research director at CNRS), this team belongs to INSERM Unit 1148 (Director D Letourneur). It was set up in 2002, and included now 22 permanent researchers/teachers and 4 technical staff members (from Inserm and University Paris 13) and several students (doctoral, post-doctoral and masters). As a multidisciplinary lab, it stands at the interface between chemistry, materials engineering, biology, biomedical imaging and cardiovascular research. The laboratory has also strong industrial partnerships and numerous patents (16 patents in the last 6 years).

One major objective of the laboratory is to develop biomaterials, based on natural and synthetic polymers, which can be used as prostheses or to reconstruct blood vessels. One direct application of this research is the development of 3D matrices for cardiovascular tissue engineering. A second program relates to local arterial gene/drug therapy, and involves developing biopolymers for functionalized stents (endovascular prostheses). A third program focus on molecular imaging of atherosclerotic diseases, for which the team is developing specific new contrast agents.

Image d’exemple